The French drugmaker Sanofi-Aventis will broaden their healthcare resources on Wednesday by moving into an agreement to develop blood glucose monitors with AgaMatrix, a private American firm.
The group will firmly enter the medical devices market, and diversify away from the traditional Sanofi business of branded prescription drugs. Chief Executive Chris Viehbacher was reported by Reuters to be looking into different medical technology, including home diagnostic units. He commented last year: “The vision of the company is to become a healthcare company (so) it’s logical to look at some kinds of devices.”
The blood glucose monitoring system will be exclusive to Sanofi and will work alongside existing diabetes treatments . Pierre Chancel, the head of the diabetes division at Sanofi, reportedly commented: “This agreement is a concrete step towards fulfilling our vision to deliver integrated solutions to patients and become the partner of choice in the field of diabetes .”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…